# CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

> **NCT07294677** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Chicago** · enrollment: 104 (estimated)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **DRUG:** Capivasertib
- **DRUG:** Venetoclax
- **DRUG:** Rituximab
- **DRUG:** Blinatumomab
- **DRUG:** Nelarabine
- **DRUG:** mini-hyperCVD

## Key facts

- **NCT ID:** NCT07294677
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2032-03
- **Final completion:** 2032-03
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07294677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07294677, "CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07294677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*